- Home
- NMCO vs CRGX Comparison
NMCO vs CRGX Comparison
Compare NMCO & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- CRGX
- Stock Information
- Founded
- NMCO 2019
- CRGX 2021
- Country
- NMCO United States
- CRGX United States
- Employees
- NMCO N/A
- CRGX N/A
- Industry
- NMCO Finance/Investors Services
- CRGX
- Sector
- NMCO Finance
- CRGX
- Exchange
- NMCO Nasdaq
- CRGX Nasdaq
- Market Cap
- NMCO 603.4M
- CRGX 628.6M
- IPO Year
- NMCO N/A
- CRGX 2023
- Fundamental
- Price
- NMCO $11.11
- CRGX $3.70
- Analyst Decision
- NMCO
- CRGX Hold
- Analyst Count
- NMCO 0
- CRGX 7
- Target Price
- NMCO N/A
- CRGX $4.67
- AVG Volume (30 Days)
- NMCO 207.6K
- CRGX 1.9M
- Earning Date
- NMCO 01-01-0001
- CRGX 03-20-2025
- Dividend Yield
- NMCO 5.43%
- CRGX N/A
- EPS Growth
- NMCO N/A
- CRGX N/A
- EPS
- NMCO N/A
- CRGX N/A
- Revenue
- NMCO N/A
- CRGX N/A
- Revenue This Year
- NMCO N/A
- CRGX N/A
- Revenue Next Year
- NMCO N/A
- CRGX N/A
- P/E Ratio
- NMCO N/A
- CRGX N/A
- Revenue Growth
- NMCO N/A
- CRGX N/A
- 52 Week Low
- NMCO $8.52
- CRGX $3.00
- 52 Week High
- NMCO $11.64
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- NMCO 70.31
- CRGX 20.88
- Support Level
- NMCO $10.69
- CRGX $3.00
- Resistance Level
- NMCO $10.98
- CRGX $3.88
- Average True Range (ATR)
- NMCO 0.12
- CRGX 0.92
- MACD
- NMCO 0.04
- CRGX -1.00
- Stochastic Oscillator
- NMCO 93.88
- CRGX 5.99
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.